Evaluation of use of risedronate as an antibiofilm agent.

Evaluation of use of risedronate as an antibiofilm agent.
J Med Microbiol. 2015 Oct 23;
Authors: Reshamwala SM, Mamidipally C, Pissurlenkar RR, Coutinho EC, Noronha SB
Abstract
Escherichia coli cra null mutants have been reported in literature to be impaired in biofilm formation. To develop E. coli biofilm-inhibiting agents for prevention and control of adherent behaviour, analogues of a natural Cra ligand, fructose-1,6-bisphosphate, were identified based on two dimensional similarity to the natural ligand. Of the analogues identified, those belonging to the bisphosphonate class of drug molecules were selected for study, as these are approved for clinical use in humans and their safety is established. Computational and in vitro studies with purified Cra protein showed that risedronate sodium interacts with residues in the fructose-1,6-bisphosphate binding site. Using a quantitative biofilm assay, risedronate sodium, at a concentration of 300-400 µM, was found to decrease E. coli and Salmonella pullorum biofilm formation by >60%. Risedronate drastically reduced adherence of E. coli cells to a rubber Foley urinary catheter, demonstrating its utility in preventing formation of biofilm communities on medical implant surfaces. The use of risedronate, either singly or in combination with other agents, to prevent formation of biofilms on surfaces is a novel finding that can be easily translated into practical applications.
PMID:...

Source: Journal of Medical Microbiology - October 23, 2015 Category: Microbiology Authors: Reshamwala SM, Mamidipally C, Pissurlenkar RR, Coutinho EC, Noronha SB Tags: J Med Microbiol Source Type: research